# We Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/we-health

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.we-health.com
- Total disclosed funding: $14M
- Latest round: Series B (Dec 27, 2023)
- Investors on record: 3

## About

Established in 2016 and based in Shanghai, We Health is a medical technology company that focuses on the research and development of genetic testing services. It acquired 19 patents and 26 CE certifications. The company was recognized as the National High-tech Enterprise. It has a testing laboratory and production base, with about 10,000 square meters. Its team members came from Fudan University, Harvard University, University of Southern California and other universities. In December 2023, We Health raised a series B1 funding for approximately 100 million.

The company's business is genetic testing services, including genetic disease testing, oncology genetic testing, and fertility testing. The genetic disease testing includes 15 categories, such as skin genetic disease testing, bone genetic disease, and blood system genetic disease testing. It has established detection platforms such as gene sequencing, structural variation detection, and QPCR.

The company will use the funding for product development and registration filing of genetic testing and tertiary prevention and control of birth defects, as well as the construction of the LDT laboratory.

## Funding rounds

- Series B, Dec 27, 2023, $14M — Yunfan Capital
- Series A, Mar 18, 2019 — MPC
- Angel, Jun 12, 2018 — Wisdomont Capital

## Investors

- Wisdomont Capital (https://capitalatlas.ai/funds/wisdomont-capital) — Angel
- MPC — Series A
- Yunfan Capital (https://capitalatlas.ai/funds/yunfan-capital) — Series B